Drug Profile
Sirolimus topical - Palvella Therapeutics/TransDerm
Alternative Names: PTX 022; QTORIN™ 3.9% rapamycin; QTORIN™ 3.9% rapamycin anhydrous gel; Rapamycin topical - Palvella Therapeutics/TransDerm; TD201Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Palvella Therapeutics; TransDerm
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Pachyonychia congenita
- Phase II Basal cell nevus syndrome; Lymphangioma
Most Recent Events
- 01 Dec 2023 Palvella Therapeutics has patent pending for anhydrous gel formulations of rapamycin in Europe, and Japan
- 01 Dec 2023 Palvella Therapeutics has patent protection for Sirolimus topical in Japan
- 16 Nov 2023 Sirolimus topical - Palvella Therapeutics/TransDerm receives Breakthrough Therapy status for Lymphangioma in USA